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Cryptococcus neoformans is a fungal pathogen that is responsible for life-threatening disease, particularly in
the context of compromised immunity. This organism makes extensive use of mannose in constructing its cell
wall, glycoproteins, and glycolipids. Mannose also comprises up to two-thirds of the main cryptococcal
virulence factor, a polysaccharide capsule that surrounds the cell. The glycosyltransfer reactions that generate
cellular carbohydrate structures usually require activated donors such as nucleotide sugars. GDP-mannose,
the mannose donor, is produced in the cytosol by the sequential actions of phosphomannose isomerase,
phosphomannomutase, and GDP-mannose pyrophosphorylase. However, most mannose-containing glycocon-
jugates are synthesized within intracellular organelles. This topological separation necessitates a specific
transport mechanism to move this key precursor across biological membranes to the appropriate site for
biosynthetic reactions. We have discovered two GDP-mannose transporters in C. neoformans, in contrast to the
single such protein reported previously for other fungi. Biochemical studies of each protein expressed in
Saccharomyces cerevisiae show that both are functional, with similar kinetics and substrate specificities.
Microarray experiments indicate that the two proteins Gmt1 and Gmt2 are transcribed with distinct patterns
of expression in response to variations in growth conditions. Additionally, deletion of the GMT1 gene yields
cells with small capsules and a defect in capsule induction, while deletion of GMT2 does not alter the capsule.
We suggest that C. neoformans produces two GDP-mannose transporters to satisfy its enormous need for
mannose utilization in glycan synthesis. Furthermore, we propose that the two proteins have distinct biological
roles. This is supported by the different expression patterns of GMT1 and GMT2 in response to environmental
stimuli and the dissimilar phenotypes that result when each gene is deleted.
Mannose is a key component of glycoconjugates in all eu-
karyotes but plays a special role in yeast, where it dominates
the carbohydrate landscape. In contrast to mammals, where
mannose is one of an array of moieties used to generate glycan
structures, a substantially more restricted range of sugars is
used in those fungi that have been examined in detail (19). The
best-studied yeast, Saccharomyces cerevisiae, uses only glucose,
N-acetylglucosamine, and mannose to build the vast majority
of its protein- and lipid-linked carbohydrate structures, and
mannose is by far the most abundant sugar in these two classes
of biosynthetic products. For example, N-linked carbohydrate
chains in this yeast are composed of a core of two N-acetyl-
glucosamine and eight mannose residues, which is further ex-
tended with up to hundreds of additional mannoses (19).
These mannose chains comprise the mannan that is an impor-
tant component of the yeast cell wall (28). Similarly, O-linked
carbohydrate chains in S. cerevisiae contain only mannose,
ranging from one to five residues, and sphingolipids contain
just mannose and inositol (16).
To generate the extensive array of mannosylated compounds
described above, yeasts must supply appropriate mannose do-
nor molecules to the enzymes that mediate their synthesis. The
simplest donor is the nucleotide sugar GDP-mannose (GDP-
Man), described by Cabib and Leloir in 1954 (11). This com-
pound is generated in the cytosol by the sequential actions of
phosphomannose isomerase, phosphomannomutase, and GDP-
Man pyrophosphorylase (57). Some GDP-Man is consumed at
the cytosolic face of the endoplasmic reticulum by incorpora-
tion into a dolichol phosphomannose lipid that is then flipped
into that organelle and used to synthesize N-linked core oli-
gosaccharides and glycosylphosphatidylinositol anchors (23).
Much of it, however, is used within the Golgi complex for the
synthesis of glycolipids and O-linked glycans (59) and for the
outer-chain elaboration of core N-linked structures (14, 36).
The location of these synthetic processes leads to a topological
problem, which is solved in yeast by the presence of specific
Golgi apparatus-localized GDP-Man transporters (1, 15, 38,
39). These proteins import the highly charged mannose pre-
cursor from the cytosol into the Golgi apparatus, operating
against a concentration gradient via an antiport mechanism
that exchanges GDP-Man for GMP. Notably, because mam-
malian cells do not perform mannosylation in the Golgi appa-
ratus, they have no GDP-Man transporters, although these
transporters have been described for plants (8, 22) and for the
protozoan parasite Leishmania donovani (33).
Our studies focus on the fungal pathogen Cryptococcus neo-
formans. This organism causes serious disease and life-threat-
ening meningitis, especially in the context of compromised
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immunity. In addition to using mannose for the synthesis of
protein- and lipid-linked structures in the manner described
above, C. neoformans incorporates this sugar into an extensive
polysaccharide capsule that surrounds the cell wall (reviewed
in reference 10). The capsule, which is required for virulence,
is composed of two polysaccharides. The larger polymer, glu-
curonoxylomannan (GXM), has a repeating structure with
monosaccharide branches of xylose and glucuronic acid linked
to a mannose backbone (13). Mutants that do not synthesize
GXM do not cause disease in experimental animal models
(12). The second polymer, galactoxylomannan, has a galactose
backbone, with side chains composed of galactose, xylose, and
mannose (56); its biological function is less well understood.
We have recently found material that reacts with anti-GXM
antibodies in post-Golgi exocytic vesicles in C. neoformans
(60). This finding indicates that capsule components are made
within secretory organelles and are then packaged into trans-
port vesicles for release at the cell surface when those vesicles
fuse with the plasma membrane. In this scenario, capsule syn-
thesis, like the other luminal processes mentioned above, will
rely on GDP-Man import via a nucleotide sugar transporter.
Mannose comprises one- to two-thirds of all sugar residues in
the capsule, depending on the serotype of C. neoformans, so
the demands for this transport will be high.
Almost 20 years ago, Hirschberg and coworkers demonstrated
GDP-Man transport in yeast by using a mixed vesicle preparation
from S. cerevisiae (3). A putative GDP-Man transporter was not
identified until almost 10 years later, however, when Turco, Bev-
erley, and colleagues showed that microsomes isolated from wild-
type L. donovani were able to import this compound, while cells
mutated in the LPG2 gene could not. The mutant cells lost the
ability to transport GDP-Man but not UDP-galactose, and the
defect was corrected by the reintroduction of the gene (33). Al-
though this initial study did not prove that Lpg2 itself was the
transport protein, subsequent work showed that Lpg2 could me-
diate GDP-Man transport activity when expressed in mammalian
cells (25), and recent reconstitution experiments proved that this
protein is indeed the transporter (51). Interestingly, Lpg2 acts as
a hexameric complex and is multifunctional, with the ability to
transport GDP-Man, GDP-arabinose, and GDP-fucose (25). The
Leishmania parasite uses GDP-Man in the synthesis of its surface
coat and related molecules. lpg2 mutants lack normal forms of
these molecules but still demonstrate normal N glycosylation,
glycosylphosphatidylinositol anchors, glycolipids, and growth
(33).
Close to the time that Lpg2 activity was described, Dean and
colleagues used a permeabilized cell assay to demonstrate
GDP-Man transport in S. cerevisiae and to implicate the yeast
protein Vrg4 in this process (15). Those authors had previously
shown that Vrg4 was required for N-linked mannosylation,
secretion, and protein sorting (44); based on in vitro transport
studies of mutant and wild-type strains, and the protein’s ho-
mology to other known nucleotide sugar transporters, they
suggested that it was the transporter itself. Subsequent work on
Vrg4 defined a conserved motif required for substrate binding,
showed that the protein occurred as a dimer and was localized
to the Golgi apparatus, and identified regions responsible for
dimerization, stability, and trafficking (1, 2, 17, 18). Unlike the
case with the Leishmania Lpg2 protein, Vrg4 is essential for
viability in yeast (44).
Although Vrg4 and Lpg2 have been the most thoroughly
examined, several other GDP-Man transporters have been
identified in the decade since these two proteins were first
implicated in this process. These transporters have been iden-
tified by sequence homology and by their ability to comple-
ment a partial mutant in VRG4, vrg4-2, but they have not been
characterized biochemically. In the fungal pathogen Candida
albicans, the single Vrg4 homolog is Golgi apparatus localized
and essential for viability, similar to S. cerevisiae Vrg4; a partial
loss of function of this protein led to mannosylation defects
that caused cell wall-associated phenotypes (39). In a related
pathogen, Candida glabrata, deletion of the single VRG4 ho-
molog was also lethal (38). Additional studies of Vrg4 have
focused on its utility as a marker of the Golgi apparatus in
fungi in both S. cerevisiae (32) and Pichia pastoris (4).
We have investigated GDP-Man transport in C. neoformans,
motivated by the central role of mannose in the major crypto-
coccal virulence factor, the capsule, and by the fact that GDP-
Man transport is a fungus-specific activity and therefore an
intriguing potential drug target. We have discovered that Cryp-
tococcus encodes and expresses two functional transporters of
GDP-Man, a unique finding among fungi. Direct assays of
activity in permeabilized cells show that the two proteins have
similar biochemical properties. However, transcriptional anal-
ysis indicates that they are not coordinately regulated and are
therefore likely to play distinct roles in cryptococcal biology.
Furthermore, deletion of the two genes results in contrasting
capsule phenotypes: gmt1 mutants have reduced capsule size
and the ability to induce capsule, while gmt2 cells appear to
have wild-type capsules.
MATERIALS AND METHODS
Strains and growth conditions. C. neoformans strains used were serotype D
strains JEC21 (MAT, from Jennifer Lodge, Saint Louis University Medical
Center) and JEC43 (MAT ura5, from Joe Heitman, Duke University Medical
Center), and serotype A wild-type strain H99 (MAT, from Gary Cox, Duke
University Medical Center). S. cerevisiae strains used were NDY5 (MAT
ura3-52 leu2-211 vrg4-2) (15) and JPY26 3d (MAT ura3-52 leu2-3,112 ade2-101
vrg4-2 dpm1) (15), provided by Neta Dean (State University of New York at
Stony Brook). All cells were grown with continuous shaking at the temperatures
indicated in the text in the following media: YPD (1% Bacto yeast extract, 2%
peptone, 2% dextrose); YNB (6.7 g/liter Bacto yeast nitrogen base [pH 7.0]) with
2% dextrose, 2% sodium acetate, 2% sodium succinate, or 1 mM H2O2; YNB
(pH 4.0) with 1 mM NaNO2; low-iron medium (LIM) (as described in reference
41) with 0.5% dextrose, 100 M EDTA, and 100 M bathophenanthroline
disulfonic acid (BPDS); LIM lacking BPDS; Dulbecco’s modified Eagle’s me-
dium (DMEM); Littman’s medium (as described in reference 29) with either
0.01 or 1 mg/ml thiamine; phosphate-buffered saline (PBS); PBS with 10% fetal
bovine serum (as described in reference 62); minimal medium with 2% glucose
but lacking uracil (as described in reference 6); or minimal medium lacking
leucine and supplemented with 0.5 M KCl.
Sequences and alignment. The S. cerevisiae Vrg4 protein sequence (GenBank
accession number NP_011290) was BLAST searched against the C. neoformans
serotype D database compiled by The Institute for Genome Research (http:
//www.tigr.org/tdb/e2k1/cna1/). Two closely related sequences were identified
and assessed using the Align X program within Vector NTI (Invitrogen, Carls-
bad, CA). The first gene (TIGR accession number CNF12620 and GenBank
accession number AAY85624) encoded a predicted protein that is 49% identical
and 65% similar to Vrg4, which we termed GMT1 for GDP-Man transporter 1.
The second gene (TIGR accession number CNG01600 and GenBank accession
number AAR96298) encoded a protein with 46% identity and 63% similarity to
Vrg4 and was named GMT2.
Gene cloning and expression in S. cerevisiae. Yeast episomal plasmids con-
taining a 2m origin of replication, the GAP (glyceraldehyde-3-phosphate de-
hydrogenase) promoter, and the URA3 marker, without or with the VRG4 se-
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quence (YEp352GAP and YEp352GAP-VRG4, respectively), were obtained
from Neta Dean. We used standard PCR techniques and primers 401 to 404 in
Table 1 to amplify GMT1 and GMT2 from JEC43 cDNA (prepared as described
in reference 47) and incorporate flanking restriction sites (5 EcoRI and 3
KpnI). The resulting segments were inserted between the corresponding sites of
YEp352GAP, and the constructs were transformed into NDY5 cells by electro-
poration for assessments of growth phenotype. Each plasmid was further mod-
ified by the insertion of LEU2 (amplified from S. cerevisiae genomic DNA using
primers 405 and 406 in Table 1) at the ApaI site of each plasmid. These
constructs were electroporated into JPY26 3d, and the resulting strains were
used for transport assays.
Hygromycin sensitivity. Cells to be tested were grown overnight in minimal
medium with 2% dextrose lacking uracil and then diluted to 1 optical density at
600 nm (OD600) unit/ml and cultured for an additional 1 h. The cells were diluted
to 0.1 OD600 units/ml, and 5 l of fivefold serial dilutions were spotted onto YPD
plates with or without 20 g/ml hygromycin B (Roche Diagnostics, Indianapolis,
IN). The plates were grown at 30°C for 3 days before imaging.
Transport assays using “semi-intact cells.” “Semi-intact cells” were prepared
as described previously by Dean and colleagues (15), with minor modifications.
Fifty-milliliter cultures of S. cerevisiae cells carrying the indicated plasmids were
grown overnight, and a portion of each culture was diluted into a 200-ml volume
to achieve an OD600 reading of 1 to 2 units on the following day. Cells were
collected by centrifugation (5 min at 1,800  g at room temperature [RT]),
resuspended at 50 OD600 units/ml in 100 mM Tris (pH 9.4)–10 mM dithiothre-
itol, and incubated at RT for 5 min. Cells were then collected as described above
and resuspended at 50 OD600 units/ml in spheroplast buffer (0.75 yeast pep-
tone, 0.7 M sorbitol, 0.5% glucose, 10 mM Tris [pH 7.5]), and the OD600 value
of a 1:100 sample in water was measured. An equal volume of 20 mg/ml of Lysing
Enzymes (Sigma, St. Louis, MO) in spheroplast buffer was added to the remain-
ing cell suspension, the cells were incubated at 30°C, and the OD600 value of 1:10
dilutions of the sample was checked every 5 min. Once the cells reached 90%
lysis, they were subjected to centrifugation (3 min at 1,500  g at RT), gently
resuspended at 50 OD600 units/ml in regeneration buffer (0.75 yeast peptone,
0.7 M sorbitol, 1% glucose), and incubated at 30°C for 20 min. Cells were
collected as described above except that it was done at 4°C, gently resuspended
at 100 OD600 units/ml in lysis buffer (0.4 M sorbitol, 0.15 M potassium acetate,
2 mM magnesium acetate, 20 mM HEPES-KOH [pH 6.8]), sedimented as
described above at 4°C, and resuspended at 300 OD600 units/ml in lysis buffer.
Portions (150 l) were aliquoted into 1.5-ml microcentrifuge tubes on ice, frozen
over liquid nitrogen for 1 h, and transferred to storage at 70°C.
For assays, semi-intact cells were thawed quickly and washed three times in 1
ml of ice-cold buffer H (20 mM HEPES [pH 6.8], 150 mM potassium acetate, 250
mM sorbitol, 5 mM magnesium acetate). Standard reaction mixtures included 50
nCi of GDP-[3H]mannose (GDP-[3H]Man) (20 Ci/mmol; American Radiola-
beled Corporation, St. Louis, MO), 3 M GDP-Man, and 30 g yeast protein
(determined by a protein assay; Bio-Rad, Hercules, CA) in a final volume of 25
l buffer H. Samples were incubated at 30°C for 5 min, incubation was stopped
by the addition of 500 l of ice-cold buffer H, and samples were immediately
centrifuged (15 min at 14,000  g at 4°C). The pellets were washed gently three
times with 1 ml cold buffer H, with brief centrifugation (30 s at 14,000  g at 4°C)
between each wash, and the membranes were then resuspended in 100 l 0.1%
Triton X-100 and incubated at RT for 30 min before 50-l samples were assessed
by scintillation counting.
Quantitative reverse transcriptase PCR. RNA for reverse transcriptase PCR
studies was prepared from 100-ml cultures of JEC21 cells grown at 30°C in YPD
medium or LIM either overnight (for exponential phase) or for 2 days (stationary
growth). Total RNA was extracted with TRIzol reagent as described previously
(30), purified using an RNeasy Maxi kit (QIAGEN, Valencia, CA) according to
the manufacturer’s instructions, and treated with DNase I (Invitrogen). Reverse
transcriptase reactions were performed with 10 g of total RNA, oligo(dT)
primers, and SuperScript II reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. Real-time PCRs used EZ RT-PCR Core Reagents
and probes that were designed using Applied Biosystems PRIMEREXPRESS
software, both obtained from Applied Biosystems. The probes and primers used
(from Invitrogen) are listed as sequences 415 to 423 in Table 1. Experiments
were performed using an ABI Prism 7000 instrument according to the manufac-
turer’s instructions, with ACT1 expression serving for normalization between
conditions. The amplification program consisted of 1 min at 60°C, 10 min at 95°C,
and 40 cycles of 15 s at 95°C alternating with 1 min at 60°C. Each PCR exper-
iment included serial dilutions of known concentrations of each DNA to be
analyzed, which were used to generate a standard curve for product quantitation.
TABLE 1. Primers and probes
Primer or probe Description Sequence (5–3)b
Expression
401 GMT1a forward primer ATCGATGAATTCCCCACAGGAATAAC
402 GMT1 reverse primer ATCGATGGTACCGCCTGGTTAGTCTT
403 GMT2 forward primer GGAATTCCATGGCCTCCTACACCC
404 GMT2 reverse primer GGGGTACCGATTACGCCTTGCTTTCTCC
405 LEU2 forward primer ATCGATGGGCCCTAAGGCCGTTTCTGACAGAGTAAAATTCTT
406 LEU2 reverse primer ATCGATGGGCCCACATACCTAATATTATTGCCTTATTAAAAATGG
Gene deletion
407 GMT1 forward primer AGGCTGTCGTTGGCAGAGGTGGTGA
408 GMT1 reverse primer GACATCTCAGCTGACGCTCTCGTCA
409 GMT2 forward primer AGGTCTCTTGCCCCTTTTCTTCCGT
410 GMT2 reverse primer TCCGATTCTGCTCGTCCTAGGGT
411 Geneticin forward primer CTAGCTAGCAGCTTCTATTGTCCAGGCTG
412 Geneticin reverse primer TTGGACCAGATGTACCCGCG
413 Nourseothricin forward primer GCCAGTGAATTGTAATACGACTCACT
414 Nourseothricin reverse primer GAAGATCTCTCTAGAACTAGTGGATCCC
Reverse transcriptase PCR
415 ACT1 forward primer CGTCACAAACTGGGACGACAT
416 ACT1 reverse primer CGACACGGAGCTCATTGTAGAA
417 ACT1 probe FAM-AGAAGATCTGGCACCATAC-MGBNFQ
418 GMT1 forward primer GGAATTCCATGGCCTCCTACACCC
419 GMT1 reverse primer CACCAGCGACACCACCAA
420 GMT1 probe FAM-CATCTCGGCCATCGC-MGBNFQ
421 GMT2 forward primer GCCAAGAAGGAGGAGGTATGC
422 GMT2 reverse primer CAGTAGCTCAGGATCGGCAGTA
423 GMT2 probe FAM-CCGCGAGCACTACT MGBNFQ
a All gene sequences are from C. neoformans except for LEU2, which is from S. cerevisiae. Sequences that introduce restriction sites are italicized.
b FAM, 6-carboxyfluorescein reporter dye; MGBNFQ, molecular groove binding nonfluorescent quencher.
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RNA for microarray analysis. Total RNA was prepared from 100-ml cultures
of the indicated strain grown to an OD600 value of 1 to 2 units. Cells were
sedimented (5 min at 6,000  g at 4°C), washed with 50 ml diethyl pyrocarbon-
ate-treated double-distilled water, and sedimented again, and the pellet was
frozen in a dry ice-methanol bath and lyophilized overnight. Each dried cell
pellet was vigorously vortex mixed with 3 ml of 0.5-mm glass beads (Biospec,
Bartlesville, OK) for 15 min and then combined with 8 ml RT TRIzol reagent
(Invitrogen) and vortex mixed for an additional 1 min. Tubes were left at RT for
5 min, mixed with 1.6 ml of chloroform, shaken gently, and incubated for 3 min
at RT. The mixture was transferred to a fresh tube, covered with parafilm, and
centrifuged (15 min at 7,600  g at RT). The upper aqueous phase was removed
to a fresh tube, slowly mixed with 1 volume of 70% ethanol, and applied to an
RNeasy Maxi column, which was centrifuged in a swinging-bucket rotor (5 min
at 3,000  g at RT). The flowthrough fraction was reapplied to the column and
eluted as described above, and the column was then washed, treated with RNase-
Free DNase (QIAGEN), washed, and eluted according to the manufacturer’s
instructions. Eluted RNA was precipitated with a 1/10 volume of 3 M sodium
acetate and 2.5 volumes of absolute ethanol on dry ice, and the pellet was
recovered by centrifugation (15 min at 8,000  g at 4°C), washed with 75%
ethanol, and allowed to air dry before resuspension in formamide at 4 mg/ml and
storage at20°C. For analysis, RNA was precipitated and resuspended in diethyl
pyrocarbonate-treated water, and the concentration and purity were determined
from absorbance readings at 260 nm and 280 nm. Total RNA quality was
assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies) according to
the manufacturer’s recommendations.
We generated a reference pool of RNA by combining 67 independent RNA
preparations from 27 combinations of strains and growth conditions. The cells
used for RNA preparation were JEC21 grown in YPD (at 25°C, 30°C, and 37°C),
YNB plus glucose (at 25°C, 30°C, 33°C, and 37°C), YNB plus acetate (at 30°C
and 37°C), YNB plus succinate (at 30°C), YNB plus NaNO2 (at 25°C), YNB plus
H2O2 (at 25°C), LIM with and without BPDS (at 37°C), DMEM (grown in room
air or 5% CO2 at 37°C), Littman’s medium (both thiamine concentrations at
37°C), and PBS (with or without fetal bovine serum at 37°C); H99 grown in YNB
plus glucose (at 30°C) and JEC43, JEC43 with pCMT1/ADE2i (52), JEC43 with
pADE2i (30), JEC43 with pAGS1i (46), JEC43 cmt1 (52), and JEC43 ags1
(47), all grown at 30°C in minimal medium lacking uracil. The pooled RNA
samples were mixed thoroughly and aliquoted for storage at 70°C so that the
same reference RNA could be used for all microarray experiments. Further
details are available upon request.
Microarray construction, hybridization, and data analysis. A total of 7,738
70-nucleotide oligonucleotide probes specific for C. neoformans serotype D were
synthesized by standard methods by Illumina Corporation (San Diego, CA) and
dissolved at 20 nM in 3 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) with 0.75 M betaine. Probes were printed in duplicate, along with control
oligonucleotides, on MWG Epoxy slides (MWG Biotech Inc., High Point, NC)
using a locally constructed linear servo arrayer (after the DeRisi model [http:
//derisilabs.ucsf.edu/]). Details of probe design and sequences are available at
http://genome.wustl.edu/activity/ma/cneoformans/array_spec.cgi.
To label RNA transcripts, first-strand cDNA was generated by oligo(dT)-
primed reverse transcription (Superscript II; Invitrogen) using the 3DNA Array
350 kit (Genisphere, Hatfield, PA) and modified oligo(dT) primers in which a
fluorophore/dendrimer-specific sequence occurs at the 5 end of the dT primer.
For cDNA synthesis, 1 l fluorophore-specific oligo(dT) primer was added to 8
g total RNA, and the solution was incubated at 80°C for 10 min and then cooled
on ice for 2 min. Each sample was then combined with 1 l RNase inhibitor
(Superase-In; Ambion, Foster City, CA), 4 l 5 first-strand buffer, 1 l de-
oxynucleoside triphosphate mix (10 mM each dATP, dCTP, dGTP, and dTTP),
2 l 0.1 M dithiothreitol, and 1 l Superscript II RNase H reverse transcriptase
(Invitrogen). Reverse transcription was allowed to proceed for 2 h at 42°C, at
which point the reaction was terminated by the addition of 3.5 l 0.5 M
NaOH–50 mM EDTA, incubated for 15 min at 65°C, and neutralized with 5 l
1 M Tris-HCl (pH 7). Samples to be cohybridized were then combined and
concentrated using Microcon YM30 microconcentrators (Millipore, Billerica,
MA) according to the manufacturer’s recommendations.
For hybridization, each sample pair (5 l) was mixed with 26 l formamide-
based hybridization buffer (vial 7; Genisphere), 2 l Array 50dT blocker (Geni-
sphere), and 19 l RNase/DNase-free water. The primary hybridization was
performed by incubating 48 l of sample on the microarray under a supported
glass coverslip (Erie Scientific, Portsmouth, NH) for 16 to 20 h at 43°C at high
humidity. The slides were then gently submerged for three sequential 11-min
incubations in 2 SSC with 0.2% sodium dodecyl sulfate (SDS) at 43°C, 2 SSC
at RT, and 0.2 SSC at RT and dried by centrifugation. Secondary hybridization
was carried out using the complementary capture reagents provided in the 3DNA
Array 350 kit (Genisphere). For each reaction mixture, 2.5 l 3DNA capture
reagent with Cy3, 2.5 l 3DNA capture reagent with Cy5, 26 l SDS-based
hybridization buffer (vial 6; Genisphere), and 21 l RNase/DNase-free water
were used. These reagents were mixed and incubated in the dark for 10 min at
80°C, followed by 15 min at 50°C. For hybridization, each slide was incubated in
the dark with 48 l of this solution under a supported glass coverslip for 3 h at
65°C at high humidity. The slides were then submerged for three sequential
11-min incubations in 2 SSC with 0.2% SDS at 65°C, 2 SSC at RT, and 0.2
SSC at RT and dried by centrifugation. To prevent fluorophore degradation, the
arrays were treated with Dyesaver (Genisphere) according to the manufacturer’s
instructions.
For data analysis, slides were scanned on a Perkin-Elmer ScanArray Express
HT scanner to detect Cy3 and Cy5 fluorescence. Laser power was kept constant
for Cy3/Cy5 scans, photomultiplier tube settings were varied for each experiment
to optimize signal intensity with the lowest possible background fluorescence,
and a low photomultiplier tube setting scan was also performed to recover signal
from saturated elements. Gridding and image analysis were performed using
ScanArray v3.0 (Perkin-Elmer, Boston, MA). Each spot was defined on a pixel-
by-pixel basis using a modified Mann-Whitney statistical test, and the local
background was subtracted from the resulting values. The mean signal and
control intensities of the on-slide duplicate spots were calculated and Lowess
normalized using GeneSpring 7.2 software (Agilent, Santa Clara, CA), with 20%
of the data used to calculate the Lowess fit at each point, and the signal-to-
Lowess-adjusted control ratios were calculated.
Gene deletion and complementation. To make gene deletion constructs, we
PCR amplified each GMT gene and then replaced each coding sequence with a
drug resistance marker. Primers listed in Table 1 were used with genomic JEC21
DNA to amplify GMT1 with 1,186 bp upstream and 590 bp downstream (primers
407 and 408) and GMT2 with 1,127 bp upstream and 1,482 bp downstream
(primers 409 and 410). These products were column purified and cloned into
pCR2.1-TOPO (Invitrogen). The geneticin drug resistance marker was PCR
amplified from plasmid pMH12-T (from Jennifer Lodge, Saint Louis University)
using primers 411 and 412 (Table 1). The forward primer introduced an NheI
restriction digest site, and the reverse primer started at the SacII restriction site,
truncating the 3 untranslated region by 479 bp. This PCR product was then
cloned into the NheI and SacII restriction sites of the pCR2.1-TOPO plasmid
containing GMT1, replacing all of the GMT1 coding sequence except for the last
17 bp. The nourseothricin resistance marker was similarly PCR amplified using
primers 413 and 414 to introduce an EcoRV restriction site at the 5 end and an
HpaI site at the 3 end. This was cloned into the NruI and HpaI blunt restriction
sites of the pCR2.1-TOPO plasmid containing GMT2, replacing all of the coding
sequence except for the last 122 bp; the remaining segment begins significantly
downstream of the sequence encoding the “GALNK” region and lacks an in-
frame start codon. Finally, the GMT flanking sequences and drug resistance
cassettes of the final constructs were amplified by PCR using primers 407 to 410,
gel purified, and biolistically transformed into JEC21 cells (55). The cells were
allowed to recover for 24 h on YPD medium, transferred onto YPD plates
containing 100 g/ml nourseothricin or geneticin, and incubated at 30°C for 3 to
5 days. Genomic DNA was extracted from drug-resistant transformants and
screened by PCR in the presence of 5% Me2SO (35) to confirm the absence of
each GMT gene and the presence of the appropriate marker in its place. DNA
blotting confirmed both gene replacements and that each marker cassette was
present only once in the genome, with no additional ectopic insertions. Details of
these studies are available upon request.
To complement the gmt1 strain, GMT1 with its flanking sequences was PCR
amplified from the TOPO plasmid described above by using primers 407 and 408.
This DNA was then biolistically transformed into the disruption strain, together
with a PCR-amplified DNA fragment containing the nourseothricin drug resis-
tance marker (generated as described above). Cotransformation was performed
as described previously (20). Transformants were identified by resistance to
nourseothricin and screened for a return to geneticin sensitivity, indicating the
replacement of the disruption marker with the wild-type sequence. Complemen-
tation was verified by PCR analysis and DNA blotting.
Capsule induction. Single colonies were inoculated into 50 ml of YPD broth
and grown overnight at 30°C. Cells were then washed with double-distilled water,
and 2  106 cells/ml were inoculated into 10 ml DMEM (Sigma) in vented T-75
flasks. Flasks were incubated at 37°C in room air or in the presence of 5% CO2
for 16 h. Cells were then collected by centrifugation and resuspended in 50 l of
water, and 5 l of this suspension was spotted onto a microscope slide with 2 l
of India ink. Cells were visualized using an Olympus BX-60 microscope (Center
Valley, PA) with a 60 objective, and random fields were photographed and
printed for manual measurement of capsule radius and cell diameter of 30 to 40
cells.
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Motivated by the importance of mannose to cryptococcal
biology and virulence, we sought the C. neoformans homolog
of the well-characterized S. cerevisiae GDP-Man transporter
Vrg4. Unexpectedly, database searches of the cryptococcal
serotype D genome (http://www.tigr.org/tdb/e2k1/cna1/) (31)
yielded two closely related sequences, with GenBank accession
numbers AAY85624 and AAR96298. We named these se-
quences GMT1 and GMT2, respectively. GMT1 encodes a 397-
amino-acid protein with 49% identity to Vrg4 (Fig. 1a), while
GMT2 encodes a 420-amino-acid protein that is 46% identical
to Vrg4 and 63% identical to the protein encoded by GMT1.
Aligning by the positions of the most highly conserved se-
quences, the cryptococcal proteins are extended at the N ter-
minus compared to S. cerevisiae Vrg4 (by 40 amino acids for
Gmt1 and 59 amino acids for Gmt2) and contain two addi-
tional small peptide insertions (four to eight residues) in the
central region of the protein as well as nine additional residues
at the C terminus. A conserved “GALNK” motif that has been
identified in Vrg4 as required for nucleotide sugar binding (17)
is present in both of the predicted cryptococcal proteins (Fig.
1b), and the C-terminal region of each bears multiple basic
residues (Fig. 1c), a feature that has been implicated in the
intracellular trafficking of related proteins (2).
We next tested whether the putative cryptococcal GDP-Man
transporters could functionally complement S. cerevisiae strain
vrg4-2. This strain bears a point mutation in the GALNK motif
(Fig. 1b) and is deficient in GDP-Man transport. Although
these cells perform enough transport to survive, they are sen-
sitive to the aminoglycoside hygromycin B and to osmotic
stress, and they display defects in Golgi apparatus glycosylation
(44). We amplified GMT1 and GMT2 from cDNA of C. neo-
formans and cloned each gene into a yeast episomal plasmid
under the control of the GAP promoter to drive strong con-
stitutive levels of expression. We then expressed each construct
in vrg4-2 cells. As shown in Fig. 2, each cryptococcal gene
complemented the vrg4-2 sensitivity to hygromycin, while plas-
mid alone did not. This proves that both cryptococcal proteins
can function as GDP-Man transporters.
To measure the levels of activity of the two cryptococcal
proteins directly, we expressed each one heterologously in S.
FIG. 1. GDP-Man transporters from fungi. (a) The level of identity between the predicted protein sequence of C. neoformans Gmt1 and S.
cerevisiae Vrg4 is indicated by the shading of each 25-amino-acid segment: 0 to 25%, white; 26 to 50%, light gray; 51 to 75%, dark gray; 76 to 100%,
black. Horizontal bars indicate the regions of sequence that are expanded in b (left bar) and c (right bar). Vertical dashed lines indicate the termini
of the shorter Vrg4. (b) Shown are aligned GALNK regions of GDP-Man transporters encoded by genes from S. cerevisiae (VRG4) (GenBank
accession number NP_011290), C. neoformans (GMT1 and GMT2), C. albicans (GenBank accession number AAK74075), and C. glabrata
(GenBank accession number AAK51897). The alignment begins with the tryptophan at position 271 of Vrg4. The originally identified components
of the sequence motif (17) are indicated in boldface type in the S. cerevisiae sequence, and * indicates the amino acid mutated to aspartic acid in
the S. cerevisiae vrg4-2 mutant. (c) Shown are the C-terminal hydrophilic residues that follow a conserved hydrophobic stretch (partially shown,
YAVA) of each transporter. Basic residues are indicated in boldface type.
FIG. 2. Both putative cryptococcal GDP-Man transporters comple-
ment the S. cerevisiae vrg4-2 mutant. Serial fivefold dilutions of vrg4-2
cells carrying the YEp vector alone or expressing the indicated genes
were plated onto YPD medium (left) or YPD medium with hygromy-
cin B, as described in Materials and Methods.
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cerevisiae and assayed GDP-[3H]Man transport in vitro, a
cross-species approach that has been effective for studies of
nucleotide sugar transporters from mammals and plants (7, 21,
40, 50, 54). To do this, we expressed each protein in vrg4-2
mutant cells that were also mutated in the gene encoding
dolichol phosphomannose synthase (DPM1) (42, 43). This mu-
tation serves to reduce background signal from radiolabeled
mannose that becomes membrane associated independent of
GDP-Man translocation into the Golgi apparatus (see above).
We then measured GDP-[3H]Man transport using dpm1 vrg4-2
mutant cells with vector alone or the same cells expressing
Gmt1, Gmt2, or Vrg4. As shown in Fig. 3, the two cryptococcal
proteins showed levels of activity that were comparable to each
other and to that of Vrg4 itself. Uptake activity in vitro was
linear for the first 6 min (not shown), comparable to data from
previous reports. The activity of each transporter was depen-
dent on protein concentration (Fig. 4a), and substrate titration
showed saturable uptake (shown for Gmt1 in Fig. 4b), with Km
values of 8.3 M for Gmt1 and 3.8 M for Gmt2 (calculated
from double-reciprocal plots) (shown for Gmt1 in Fig. 4b,
inset). These are comparable to the Km of 6.6 M determined
for GDP-Man transport by reconstituted Leishmania Lpg2
(51) and to typical Km values for other nucleotide sugar trans-
porters (between 1 and 10 M) (24).
The only function demonstrated for Vrg4 in S. cerevisiae is
the transport of GDP-Man. However, Lpg2 from Leishmania
major is multifunctional and can transport GDP-arabinose and
GDP-fucose in addition to GDP-Man (less efficiently in mem-
brane assays in vitro) (25) but at comparable levels with re-
constituted protein (24). While this was a unique finding at the
time that it was initially observed, in recent years, multiple
substrates have been demonstrated for several additional nu-
cleotide sugar transporters (5, 9, 37, 40, 48, 50). To assess other
potential substrates of the cryptococcal proteins, we performed
GDP-[3H]Man transport assays in the presence of excess
amounts of the nonradiolabeled compounds indicated in Table
2. While GDP and GDP-Man substantially reduced transport
activity, the inhibitory effect of GDP-fucose was not statisti-
cally significant (P 	 0.90 for Gmt1 and P 	 0.66 for Gmt2 by
Z test) (we did not test GDP-arabinose because it is not com-
mercially available). This indicates that the transporter either
does not transport this compound or does so with extremely
low efficiency.
The two cryptococcal transporters are similar in terms of
vrg4-2 complementation and in vitro transport characteristics.
However, these studies were all performed in an exogenous
system, so we next investigated the expression of these genes in
C. neoformans. We performed quantitative reverse transcrip-
tase PCR studies of wild-type cryptococcal cells cultured under
three growth conditions by using either a rich medium that is
FIG. 3. GMT1 and GMT2 expressed in S. cerevisiae enable GDP-
Man transport in vitro. vrg4-2 dpm1 mutant cells expressing the indi-
cated genes were permeabilized, washed, and used to assay GDP-
[3H]Man transport (see Materials and Methods). Assays were done for
10 min at 30°C, with 15 g of protein per reaction.
FIG. 4. Activity of Gmt1 and Gmt2 is saturable and dependent on
protein and substrate. Assays were performed for 5 min at 30°C using
the indicated amounts of protein in the presence of 3 M GDP-Man
(A) or the indicated GDP-Man levels with 30 g of protein (B).
Circles, Gmt1; diamonds, Gmt2. Average and standard error values of
triplicate assays are plotted. The inset of B is a double-reciprocal plot
of the same data points.
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standard for laboratory growth or an LIM known to induce
capsule production in vitro. Analysis of four independent RNA
preparations for each condition showed that both genes were
transcribed, although GMT1 transcripts were more abundant.
The mean ratios of expression of GMT1 compared to that of
GMT2 were 5.4 
 0.3 for cells undergoing exponential growth
in rich medium (YPD), 5.3 
 1.2 for cells in stationary phase
in YPD medium, and 7.9 
 1.3 for cells undergoing exponen-
tial growth in LIM (see Materials and Methods).
To examine GMT1 and GMT2 expression in more detail, we
performed microarray analysis to assess the expression of each
gene under a variety of growth conditions (see Materials and
Methods). The media that have been historically developed for
C. neoformans culture are those that either alter capsule pro-
duction or induce cell stress, so a selection of such conditions
was used (see Materials and Methods). In most media tested,
the expression of GMT1 exceeded that of GMT2 by several-
fold, consistent with the results from the growth conditions
tested by quantitative reverse transcriptase PCR. The ratio of
expression of the two genes varied, ranging from 1 for samples
grown in PBS to over 14 for samples grown in DMEM (data
not shown).
We next examined the influence of environment on the
regulation of GMT1 and GMT2 independently. To do this, we
assessed the expression of each gene in our set of growth
conditions relative to expression of the same gene in a refer-
ence pool of mixed RNA samples (see Materials and Meth-
ods). This experiment allowed us to draw several conclusions.
First, the expression of both genes changed with growth con-
ditions (Fig. 5). Second, under the conditions tested, GMT1
expression (Fig. 5, top panel) was fairly stable, exhibiting only
a 3.5-fold difference overall. In contrast, GMT2 expression
(Fig. 5, lower panel) was quite variable, with a range of over
17-fold. Finally, the two genes are not coordinately regulated.
For example, GMT1 expression was decreased by over 40%
relative to the reference pool in PBS, while expression of
GMT2 was increased severalfold. Expression of these genes
reversed during growth in low-thiamine Littman’s medium,
where GMT1 expression was increased 25%, while the ex-
pression of GMT2 was reduced by almost half.
Our expression studies suggested that Gmt1 and Gmt2 play
different roles in the biology of Cryptococcus. To address this
hypothesis, we replaced the gene encoding each transporter
with a drug resistance marker and assessed the resulting dis-
ruption strains. Both mutants grew at the same rate as wild-
type cells at 30°C (growth curves were performed as described
in reference 47) (not shown). However, colonies of gmt1 cells
appeared to be duller than those of the wild type, the gmt2
mutant, or the complemented gmt1 mutant (not shown). This
feature is typical of cells with a reduced or absent capsule, a
finding that intrigued us because of the extensive mannosyla-
tion of capsule polysaccharides.
To pursue the possibility that gmt1 cells had altered cap-
sules, we used India ink staining and light microscopy to assess
the capsule sizes of disruption and wild-type strains. Cells
disrupted in GMT1 had smaller capsules than the wild type in
the DMEM medium tested, with a radius of 0.67 
 0.05 m
compared to 1.06 
 0.06 m (P value of 0.0001 by Student’s
t test). We know that cryptococcal cells modulate capsule pro-
duction in response to environment both in vitro and in vivo
(26, 49, 58, 62), a process that is likely to be significant for
pathogenesis. We therefore probed the mutant phenotype fur-
ther by testing the response of gmt1 cells to growth in the
same medium under a 5% CO2 atmosphere, a condition that
leads to the formation of large capsules (62). When grown this
way, the gmt1 mutant cells exhibited a striking defect in
capsule formation (Fig. 6), which increased only slightly, to
0.94 
 0.05 in radius compared to 3.29 
 0.08 for the wild type
FIG. 5. GMT1 and GMT2 are not coordinately expressed. Expres-
sion of each gene is plotted normalized to its expression in a reference
pool (indicated by the dotted line). Values shown are the median
values from three separate experiments using independently prepared
RNA samples and performed in duplicate. The RNA samples indi-
cated were prepared from JEC21 cells, which were grown overnight
in the following media: YPD, LIM (low Fe), LIM without BPDS (low
Fe  BPDS), DMEM, DMEM plus CO2, PBS, PBS plus fetal calf
serum (FCS), Littman’s medium with 1 g/ml thiamine (high thia-
mine), Littman’s medium with 0.01 g/ml thiamine (low thiamine),
YNB, YNB plus H2O2 (H2O2), or YNB plus NaNO2 (NaNO2). All
cells were grown at 37°C except for YPD and YNB medium, which
were grown at 30°C, and YNB medium with H2O2 or NaNO2, which
was grown at 25°C. All growth was in room air, except the DMEM-
plus-CO2 sample, which was grown in a 5% CO2 atmosphere. See
Materials and Methods for additional details of growth media, prep-
aration of the reference pool, and analysis.







 3 13 
 4
GDP-Man 19 
 5 19 
 5
GDP-fucose 83 
 13 94 
 16
a All values were normalized to assays with no added inhibitor (100%). Aver-
age values and standard errors shown were calculated from the median values of
six independent experiments.
b Nonradioactive compounds were present at a final concentration of 23 M,
a 230-fold molar excess over radiolabeled substrate.
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(P value of 0.0001). As shown in Fig. 6, this defect was
reversed in gmt1 cells complemented with GMT1 (3.12 

0.12) (P value of 0.22 compared to the wild type). gmt2
capsules were also similar to those of the wild type under these
inducing conditions (3.36 
 0.08) (P value of 0.56 compared to
the wild type).
DISCUSSION
C. neoformans has two functional Golgi apparatus GDP-
Man transporters, which bear extensive homology to Vrg4 of S.
cerevisiae. One difference between the transporters from these
two organisms is the presence of extended N-terminal se-
quences in the cryptococcal proteins (Fig. 1a). The N terminus
of Vrg4 has been implicated in protein localization (18), but
our complementation studies (Fig. 2) show that the cryptococ-
cal versions function well in S. cerevisiae, suggesting that the
extended sequences still allow for correct localization. In ac-
cordance with their demonstrated activity, and similar to other
proteins in this class (34), the cryptococcal transporters have
highly conserved GDP-Man binding domains (17). They also
have several basic residues in their C-terminal tails, a feature
that has been implicated in recycling to the endoplasmic retic-
ulum (2).
The presence of two GDP-Man transporters in C. neofor-
mans is unique compared to the other fungi studied in this
regard to date: C. albicans, C. glabrata, P. pastoris, and S.
cerevisiae. Beyond yeast, several examples of multiple nucleo-
tide sugar transporters with overlapping functions have been
demonstrated. These include multiple UDP-galactose trans-
porters described for plants (7), parasites (11a), and mammals
(27, 61) and a set of five Golgi apparatus-localized proteins of
Arabidopsis thaliana that all exhibit GDP-Man transport activ-
ity (8, 22).
One key question is whether Gmt1 and Gmt2 play different
roles in the biology and pathogenesis of C. neoformans. Our
expression data suggest that they do, because they demonstrate
distinct patterns of regulation in response to growth condi-
tions, despite similar biochemical characteristics. In particular,
GMT1 is modestly regulated, with only a fewfold difference in
expression under the growth conditions that we tested, while
the expression of GMT2 is more dramatically modulated (Fig.
5). Furthermore, under all conditions but one, the magnitude
of the observed changes in expression differed between the
genes, and in several cases, these changes were in opposite
directions.
Several of the growth conditions that we tested yielded cells
with enlarged capsules, for example, growth in DMEM under
CO2 compared to growth in room air or growth in PBS with
fetal calf serum as opposed to growth in PBS alone. However,
we did not observe any correlation between the expression of
either GMT gene and capsule size (not shown). This may be
because the diverse conditions sampled here also affect the
overall metabolic state of the cell and thus simultaneously alter
the transport requirements for GDP-Man needed to synthesize
other glycoconjugates.
Intrigued by the distinct expression patterns of two very
similar genes, we deleted GMT1 and GMT2. Both deletion
strains grow well in culture, but gmt1 cells demonstrate re-
duced capsule and a marked defect in capsule induction (Fig.
6), while gmt2 cells are wild type. This finding links GDP-Man
transport and capsule synthesis, supporting our recent conclu-
sion that capsule synthesis occurs inside subcellular organelles
(60).
A further puzzle is how Gmt1 and Gmt2 could serve differ-
ent biological functions while performing the same biochemi-
cal activity. It may be that these proteins are differentially
localized, perhaps to serve distinct biosynthetic pathways. We
know that localization is critical for the appropriate function of
these proteins, because the S. cerevisiae protein Hvg1p, a close
homolog of Vrg4 that is resident in the endoplasmic reticulum,
cannot complement vrg4-2 cells unless it is engineered to reach
the Golgi apparatus (18). In contrast, when the cryptococcal
transporters are expressed in yeast, both are probably localized
to the Golgi apparatus, since they do complement vrg4-2 cells.
It is possible that the two transporters occupy different regions
of the Golgi apparatus in C. neoformans. A variety of proteins
have been localized to subcompartments of the Golgi appara-
tus in mammalian systems (45), but current techniques do not
allow sufficient resolution to examine protein localization
FIG. 6. gmt1 cells are unable to form large capsules. Cells of the
indicated strains were grown in DMEM in a 5% CO2 atmosphere and
then mixed with India ink as described in Materials and Methods and
examined by light microscopy. The clear halo surrounding the refrac-
tile cell wall corresponds to the space occupied by the capsule, into
which the ink particles do not penetrate. wt, wild type; gmt1, gmt1;
GMT1, gmt1 complemented with GMT1; gmt2, gmt2. All images are
to the same scale; scale bar, 4 m.
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within the smaller unstacked Golgi apparatus of Cryptococcus.
Another possibility is that the two transporters associate with
different synthetic machinery within the cell. In mammalian
systems, there is precedent for the specific association of a
nucleotide sugar transporter and a glycosyltransferase, which
consumes the corresponding transport substrate (53).
Ultimately, distinguishing the biological roles of the proteins
encoded by GMT1 and GMT2 must await detailed biochemical
and morphological examinations of the two mutant strains to
examine the effects of these mutations on other mannose-
requiring processes and on cryptococcal virulence. The latter
studies will be particularly important, since GDP-Man trans-
porters are present in a variety of pathogens including fungi
and parasites. Because the mammalian hosts of these organ-
isms do not have such proteins, GDP-Man transporters have
been suggested as potential targets of antimicrobial chemo-
therapy, a direction that merits further investigation.
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